Terahertz Front End Technology and Deployment for Ultra-High Capacity Links

Author(s):  
Quang Trung Le ◽  
Roberto Llorente ◽  
François Magne ◽  
Claudio Paoloni ◽  
Antonio Ramírez
Keyword(s):  
2016 ◽  
Vol 52 (3) ◽  
pp. 2737-2746 ◽  
Author(s):  
Thiago Morais Parreiras ◽  
Julio Cesar Guerra Justino ◽  
Anderson Vagner Rocha ◽  
Braz de Jesus Cardoso Filho

Author(s):  
Thiago M. Parreiras ◽  
Anderson V. Rocha ◽  
Julio C. G. Justino ◽  
Braz de J. Cardoso Filho

Author(s):  
Shaohua Lu ◽  
Weidong Hu ◽  
Xiaojun Hu

Due to their low cost and improved safety compared to lithium-ion batteries, sodium-ion batteries have attracted worldwide attention in recent decades.


1990 ◽  
Vol 137 (1) ◽  
pp. 57 ◽  
Author(s):  
M. Steyaert ◽  
Z. Chang
Keyword(s):  

1987 ◽  
Vol 58 (03) ◽  
pp. 936-942 ◽  
Author(s):  
Lindsey A Miles ◽  
Edward F Plow

SummaryGlu-plasminogen binds to platelets; the monocytoid line, U937, and the human fetal fibroblast line, GM1380 bind both plasminogen and its activator, urokinase. This study assesses the interaction of these fibrinolytic proteins with circulating human blood cells. Plasminogen bound minimally to red cells but bound saturably and reversibly to monocytes, granulocytes and lymphocytes with apparent Kd values of 0.9-1.4 μM. The interactions were of high capacity with 1.6 to 49 × 105 sites/cell and involved the lysine binding sites of plasminogen. Both T cells and non-rosetting lymphocytes and two B cell lines saturably bound plasminogen. Urokinase bound saturably to gianulocytes, monocytes, non-rosetting lymphocytes and a B cell line, but minimally to T cells, platelets and red cells. Therefore, plasminogen binding sites of high capacity, of similar affinities, and with common recognition specificities are expressed by many peripheral blood cells. Urokinase receptors are also widely distributed, but less so than plasminogen binding sites. The binding ol plasminogen and/ or urokinase to these cells may lead to generation of cell- associated proteolytic activity which contributes to a variety of cellular functions.


1984 ◽  
Vol 51 (03) ◽  
pp. 349-353 ◽  
Author(s):  
C Caranobe ◽  
P Sié ◽  
F Fernandez ◽  
J Pris ◽  
S Moatti ◽  
...  

SummaryA simultaneous investigation of the kinetics of serotonin (5 HT) uptake and of binding sites was carried out in the platelets of normal subjects and of 10 patients affected with various types of myeloproliferative disorders (MD). The 5 HT uptake was analysed according to the Lineweaver-Burk and the Eadie-Hofstee methods. With the two methods, the patient’s platelets exhibited a dramatic reduction of the Vi max and of the Km; in some patients the Eadie-Hofstee analysis revealed that a passive diffusion phenomenon is superimposed on the active 5 HT uptake at least for the higher concentration used. The binding data were analysed with the Scatchard method. Two classes of binding sites (high affinity - low capacity, low affinity - high capacity) were found in normal subjects and patients. Pharmacological studies with imipramine, a specific inhibitor of 5 HT uptake, suggested that both the sites are involved in 5 HT uptake. The number of both binding sites was significantly decreased in patient’s platelets while the affinity constants of these binding sites were not significantly reduced in comparison with those of the control subjects. No correlations were found between Vi max, Km and the number of binding sites. These results suggest that a reduction in the number of platelet membrane acceptors for 5 HT commonly occurs in myeloproliferative disorders but does not provide a full explanation of the uptake defect.


Sign in / Sign up

Export Citation Format

Share Document